THE ROLE OF Ki-67, p53 and bcl-2 ANTIGENS IN THE PROGNOSIS OF CLINICAL COURSE OF TRANSITIONAL CELLULAR CANCER OF THE URINARY BLADDER

THE AIM. The goal of present investigation was to study the expression of Ki-67, p53 and bcl-2 antigens and their connection with clinic-morphological characteristics of the tumor, and also the clinical flow of the disease. PATIENTS AND METHODS. The materials of the clinical investigation of 16 patients with transitional cellular carcinoma of the urinary bladder was retrospectively studied. Immunohystochemical reaction with Ki-67, p53 and bcl-2 antibodies took place. The received histological and immunohystochemical data was co-analyzed with the follow-up results after the patients during 5 years. RESULTS. The high level of proliferative activity of the transitional cell carcinoma correlated with the lower differentiation stage of the tumor tissue (r=0,70; p=0,003) and shorter period of recurrence absence (r=0,67; p=0,078). For the carcinomas with the higher number of p-53 positive nucleae was more characteristic the lower stage of the differentiation (r=0,47; p=0,067), faster recurrence (r=72; p=0,068) and lower life duration of the patients (r=0,72; p=0,087). The apoptosis activity increased with the decrease of the differentiation stage of the tumor (r=0,67; p=0,04). Was discorered a positive correlation between tumor cell proliferation and apoptosis failure (r=0,67; p=0,04). CONCLUSION. As a result of the conducted experiment we stated that investigated antigens have a prognostic value, as a result of their close connection with the stage differentiation of the transitional cell carcinoma. Besides that the hyper expression of p53 protein was interconnected with the speed of the tumor recurrence and survival of the patients.

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of major cancers in 1985. Int J Cancer 1993;54:594-606

2. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcomein patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-7373

3. Lebret T, Becette V, Herve JM. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000; 37:654-659

4. Pich A, Chiusa L, Formiconi A. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;95:784-790

5. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopez C. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumor. Ann Oncol 2003;14(9):1419-1424

6. Quintero A, Alvarez-Kindelan J, Luque RJ. Ki-67 MIB1 labeling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83-88

7. Zlotta AR, Noel JC, Fayt I, Drowart, Van Vooren JP, Huygen K, Simon J, Schulman CC. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999;161(3):792-798

8. Hollstein M, Sidransky D, Volgelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49

9. Lane DP. Cancer. P53, guardian of the genome. Nature 1992;358:15

10. Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Hofner K, Tan HK, Jonas U. P53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995;31A(13-14):2243-2247

11. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL. P53 and Ki-67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41(2):182-8; discussion 188-189

12. Lipponen PK. Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53(3):365-370

13. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996; 78(8):1762-1774

14. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996;28920:135-140

15. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Barterlink H, Verheij M. Prognostic factors in transitional cell cancer of the bladder: an emerging role for bcl-2 and p53. Radiother Oncol 2001;61(2):169-175

16. Atug F, Turkeri L, Ozyurek M, Akdas A. Bcl-2 and p53 overexpression as risk factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 1998; 30(4):455-461

17. Bol MGW, Baak JPA, van Diermen B, Buhr-Wildhagen S, Janssen EAM, Kjellevold KH, Kruse AJ, Mestad O, Ogreid P. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol 2003; 56(6):447-452